In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia
Open Access
- 1 October 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (10) , 6262-6265
Abstract
Tedizolid is a novel, expanded-spectrum oxazolidinone with potent activity against a wide range of Gram-positive pathogens. A total of 425 isolates of Gram-positive bacteria were obtained consecutively from patients with acute bacterial skin and skin structure infections (ABSSSIs) or pneumonia. These isolates included methicillin-susceptible Staphylococcus aureus (MSSA) ( n = 100), methicillin-resistant Staphylococcus aureus (MRSA) ( n = 100), Streptococcus pyogenes ( n = 50), Streptococcus agalactiae ( n = 50), Streptococcus anginosus group ( n = 75), Enterococcus faecalis ( n = 50), and vancomycin-resistant enterococci (VRE) ( Enterococcus faecium ) ( n = 50). The MICs of tedizolid and linezolid were determined by the agar dilution method. Tedizolid exhibited better in vitro activities than linezolid against MSSA (MIC 90 s, 0.5 versus 2 μg/ml), MRSA (MIC 90 s, 0.5 versus 2 μg/ml), S. pyogenes (MIC 90 s, 0.5 versus 2 μg/ml), S. agalactiae (MIC 90 s, 0.5 versus 2 μg/ml), Streptococcus anginosus group (MIC 90 s, 0.5 versus 2 μg/ml), E. faecalis (MIC 90 s, 0.5 versus 2 μg/ml), and VRE (MIC 90 s, 0.5 versus 2 μg/ml). The tedizolid MICs against E. faecalis ( n = 3) and VRE ( n = 2) intermediate to linezolid (MICs, 4 μg/ml) were 1 μg/ml and 0.5 μg/ml, respectively. The tedizolid MIC 90 s against S . anginosus , S. constellatus , and S. intermedius were 0.5, 1, and 0.5 μg/ml, respectively, and the rates of susceptibility based on the U.S. FDA MIC interpretive breakpoints to the isolates were 16%, 28%, and 72%, respectively. Tedizolid exhibited 2- to 4-fold better in vitro activities than linezolid against a variety of Gram-positive cocci associated with ABSSSIs and pneumonia. The lower susceptibilities of tedizolid against isolates of S. anginosus and S. constellatus than against those of S. intermedius in Taiwan were noted.Keywords
This publication has 17 references indexed in Scilit:
- In vitro activity of linezolid as assessed through the 2013 LEADER surveillance programDiagnostic Microbiology and Infectious Disease, 2015
- Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2015
- Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and EuropeDiagnostic Microbiology and Infectious Disease, 2015
- Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialThe Lancet Infectious Diseases, 2014
- Changing aetiology of healthcare-associated bloodstream infections at three medical centres in Taiwan, 2000–2011Epidemiology and Infection, 2013
- Trends in Susceptibility of Vancomycin-Resistant Enterococcus faecium to Tigecycline, Daptomycin, and Linezolid and Molecular Epidemiology of the Isolates: Results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) Study, 2006 to 2010Antimicrobial Agents and Chemotherapy, 2012
- In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococciJournal of Antimicrobial Chemotherapy, 2011
- Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP studyJournal of Antimicrobial Chemotherapy, 2011
- Infections caused by Gram-positive bacteria: a review of the global challengeJournal of Infection, 2009
- Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA MethyltransferaseJournal of Clinical Microbiology, 2008